Skip to content
Sign in

LEXX · NASDAQ

Lexaria Bioscience (LEXX) Stock Price & Fundamentals

$372.19−0.93%−$3.49End-of-day price as of Oct 9, 2026

Lexaria Bioscience (LEXX) closed at $372.19 on Oct 9, 2026, down 0.93% from the previous close of $375.68.

Share price, past year

1Y +21.48%

52-week range $268.11 – $375.68. Daily closing prices.
Monthly closing prices
Last closing price of each month
DateClose
Oct 9, 2026$372.19
Sep 30, 2026$366.48
Aug 31, 2026$344.15
Jul 31, 2026$319.56
Jun 30, 2026$315.76
May 29, 2026$297.38
Apr 30, 2026$288.33
Mar 31, 2026$297.97
Feb 27, 2026$272.57
Jan 30, 2026$284.92
Dec 31, 2025$293.00
Nov 28, 2025$292.71
Oct 31, 2025$311.46

Key statistics

Market cap
$9.23B
P/E (TTM)
—
EPS (TTM)
−$0.35
Revenue (TTM)
$194.00K
Net income (TTM)
−$7.73M
Shares outstanding
24.8M
Dividend yield
—
52-week range
$268.11 – $375.68

Lexaria Bioscience's market cap is $9.23B, based on a share price of $372.19 and 24.8M shares outstanding as of May 31, 2026.

Financials

Lexaria Bioscience reported revenue of $705.92K for fiscal 2025, up 52.05% from fiscal 2024.

Lexaria Bioscience reported a net loss of $11.90M in fiscal 2025.

Annual revenue

FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Annual revenue by fiscal year; the table below lists the values.
Lexaria Bioscience annual financials by fiscal year, from SEC filings
Fiscal yearRevenueGrowthNet incomeNet marginEPS (diluted)Free cash flow
FY2025ended Aug 31, 2025$705.92K+52.1%−$11.90M−1,686.0%−$0.66−$10.48M
FY2024ended Aug 31, 2024$464.28K+105.2%−$5.80M−1,248.3%−$0.47−$5.00M
FY2023ended Aug 31, 2023$226.21K−11.4%−$6.66M−2,946.4%−$1.01−$5.91M
FY2022ended Aug 31, 2022$255.40K−64.7%−$7.27M−2,846.3%—−$4.93M
FY2021ended Aug 31, 2021$722.74K+129.6%−$4.03M−557.2%−$0.95—
FY2020ended Aug 31, 2020$314.79K+41.4%−$4.08M−1,297.6%−$1.47−$2.62M
FY2019ended Aug 31, 2019$222.61K−48.6%$4.10M1,841.8%−$0.05−$3.65M
FY2018ended Aug 31, 2018$433.29K+580.9%$6.60M1,523.2%−$0.09—
FY2017ended Aug 31, 2017$63.64K+56.3%−$1.93M−3,031.9%−$0.03−$1.55M
FY2016ended Aug 31, 2016$40.72K—−$1.28M−3,136.8%−$0.03−$663.95K
Lexaria Bioscience quarterly results
QuarterRevenueNet incomeEPS (diluted)
Q3 FY2026ended May 31, 2026$0.00−$1.99M−$0.08
Q2 FY2026ended Feb 28, 2026$20.00K−$1.45M−$0.06
Q1 FY2026ended Nov 30, 2025$0.00−$1.60M−$0.07
Q4 FY2025ended Aug 31, 2025$174.00K−$2.70M−$0.14
Q3 FY2025ended May 31, 2025$174.00K−$3.79M−$0.21
Q2 FY2025ended Feb 28, 2025$174.00K−$2.71M−$0.15
Q1 FY2025ended Nov 30, 2024$183.92K−$2.70M−$0.16
Q4 FY2024ended Aug 31, 2024$84.00K−$2.18M−$0.15

Company profile

Name
Lexaria Bioscience Corp.
Ticker
LEXX
Exchange
NASDAQ
Industry (SEC SIC)
Pharmaceutical Preparations
Headquarters
100 - 740 Mccurdy Road, Kelowna, A1 V1X 2P7
Incorporated in
NV
Fiscal year ends
August
SEC CIK
0001348362

Recent SEC filings

Frequently asked questions

What is Lexaria Bioscience's stock price?

Lexaria Bioscience (LEXX) closed at $372.19 on Oct 9, 2026, down 0.93% from the previous close of $375.68.

What is Lexaria Bioscience's market cap?

Lexaria Bioscience's market cap is $9.23B, based on a share price of $372.19 and 24.8M shares outstanding as of May 31, 2026.

How much revenue does Lexaria Bioscience make?

Lexaria Bioscience reported revenue of $705.92K for fiscal 2025, up 52.05% from fiscal 2024.

Does Lexaria Bioscience pay a dividend?

Lexaria Bioscience's recent filings report no dividends declared over the last four quarters.

Sources and methodology

Fundamentals come from Lexaria Bioscience Corp.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures